Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 675Breast Neoplasms 265Uterine Cervical Neoplasms 240Carcinoma, Non-Small-Cell Lung 218Endometrial Neoplasms 201Fallopian Tube Neoplasms 187Carcinoma, Ovarian Epithelial 175Colorectal Neoplasms 164Stomach Neoplasms 152Pancreatic Neoplasms 144Neoplasms 143Melanoma 118Lung Neoplasms 112Carcinoma, Renal Cell 111Triple Negative Breast Neoplasms 108Prostatic Neoplasms 108Squamous Cell Carcinoma of Head and Neck 98Neoplasm Metastasis 96Esophageal Neoplasms 90Urinary Bladder Neoplasms 85Head and Neck Neoplasms 83Sarcoma 69Small Cell Lung Carcinoma 64Carcinoma, Hepatocellular 64Colonic Neoplasms 56Carcinoma, Transitional Cell 49Kidney Neoplasms 41Testicular Neoplasms 38Peritoneal Neoplasms 37Anus Neoplasms 34

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Metastatic Breast Cancer × Gynecologic × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡